Operating
Change in Other Liabilities
Pfizer Change in Other Liabilities remained flat by 0.0% to -$916.75M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 17.7%, from -$778.75M to -$916.75M. Over 4 years (FY 2021 to FY 2025), Change in Other Liabilities shows a downward trend with a -33.5% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
A decrease indicates the company is paying down its miscellaneous obligations, which is a use of cash.
Detailed definition
This reflects the net change in various short-term and long-term obligations, such as deferred revenue, accrued expenses...
Peer comparison
For companies with large subscription or service businesses, changes in deferred revenue (a component here) are a key indicator of future growth.
Metric ID:
cf_change_in_other_liabilitiesHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $18.72B | -$1.45B | $595.00M | -$3.12B | -$3.67B |
| YoY Change | — | -107.7% | +141.1% | -623.5% | -17.7% |
Range-$3.67B – $18.72B
CAGR-33.5%
Avg YoY Growth-152.0%
Median YoY Growth-62.7%
Current Streak2 years decline
Change in Other Liabilities at Other Companies
Frequently Asked Questions
- What is Pfizer's change in other liabilities?
- Pfizer (PFE) reported change in other liabilities of -$916.75M in Q4 2025.
- How has Pfizer's change in other liabilities changed year-over-year?
- Pfizer's change in other liabilities decreased by 17.7% year-over-year, from -$778.75M to -$916.75M.
- What is the long-term trend for Pfizer's change in other liabilities?
- Over 4 years (2021 to 2025), Pfizer's change in other liabilities has grown at a -33.5% compound annual growth rate (CAGR), from $18.72B to -$3.67B.
- What does change in other liabilities mean?
- The change in miscellaneous debts and obligations the company owes to others.